T. Rowe Price Associates’s Protalix BioTherapeutics PLX Stock Holding History

T. Rowe Price Associates’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$125K	Hold	53,478	–	–	﹤0.01%	3111
2026 Q1	$117K	Buy	53,478 +18,200	+52%	+$45.2K	﹤0.01%	2967
2025 Q4	$64K	Hold	35,278	–	–	﹤0.01%	3009
2025 Q3	$79K	Hold	35,278	–	–	﹤0.01%	2962
2025 Q2	$53K	Buy	+35,278	New	+$72.2K	﹤0.01%	3000
2024 Q2	–	Sell	-15,982	Closed	-$21K	–	3002
2024 Q1	$21K	Hold	15,982	–	–	﹤0.01%	2927
2023 Q4	$29K	Hold	15,982	–	–	﹤0.01%	2855
2023 Q3	$27K	Buy	15,982 +4,535	+40%	+$8.14K	﹤0.01%	2838
2023 Q2	$23K	Buy	+11,447	New	+$27.3K	﹤0.01%	2861

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

T. Rowe Price Associates's PLX Position: Q2 2026 in Review

T. Rowe Price Associates held its Protalix BioTherapeutics (PLX) position steady in Q2 2026 at 53,478 shares worth $125K. The position accounts for ﹤0.01% of the portfolio, ranked #3111.

T. Rowe Price Associates first reported a position in PLX in Q2 2023 and has held it in 9 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

T. Rowe Price Associates held 53,478 shares of Protalix BioTherapeutics worth $125K as of Q2 2026.
T. Rowe Price Associates left its Protalix BioTherapeutics share count unchanged in Q2 2026.
Protalix BioTherapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3111 holding.
T. Rowe Price Associates first reported a position in Protalix BioTherapeutics in Q2 2023 and has held it in 9 quarters since.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.